A Study of TRK-950 in Patients With Advanced Solid Tumors
← catalyst calendarNCT05423262 · readout ≤ 499 d
Sponsored by Toray Industries, Inc (industry) · 3402.T — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
49estimated
Sites
10
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-06 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor
- Melanoma
Interventions
- Biological: TRK-950
- Biological: TRK-950
- Biological: TRK-950
- Drug: Nivolumab
- Biological: TRK-950
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with dose-limiting toxicities (DLTs) (Part 1 and 2)
measured Up to Day 28
Number of participants with adverse events (AEs) (Part 1 and 2)
measured through study completion, an average of 1 year
Number of participants with adverse events of special interest (AESIs) (Part 1 and 2)
measured through study completion, an average of 1 year
Number of participants with serious adverse events (SAEs) (Part 1 and 2)
measured through study completion, an average of 1 year
Objective response rate (ORR) (Part 3)
measured Up to approximately 12 months
Publications
- PMID 41979863 — linked by the registry
- PMID 37082579 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · 3402.T's whole pipeline · Catalyst calendar · Every registered study · What changed